No Additional Information
Trajenta contains Linagliptin as the active ingredient which is a Dipeptidyl peptidase inhibitor. It works by increasing the release of insulin from the pancreas and decreasing the hormones that raise blood sugar levels. This reduces the fasting and postmeal sugar levels.
It increases and prolongs incretin hormones activity which is inactivated hormone which is inactivated by DPP -4 enzyme. Incretins regulate glucose homeostasis by increasing insulin synthesis and release from pancreatic beta cells and reducing glucagon secretion from pancreatic alpha cells.
Trajenta Tablet is used in the treatment of type 2 diabetes. It is used in addition to diet and exercise to improve blood sugar control in adults with type 2 diabetes.
Direction to Use
Common Side Effects are :
Hypoglycaemia (low blood sugar level) in combination with insulin or sulphonylurea, Headache, Nasopharyngitis (inflammation of the throat and nasal passages).